Italia markets closed

AnaptysBio, Inc. (0HFQ.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
30,60+1,32 (+4,51%)
Alla chiusura: 03:06PM BST
Schermo intero
Chiusura precedente29,28
Aperto0,00
Denaro0,00 x N/D
Domanda0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume170
Media Volume169
Capitalizzazione703,534M
Beta (mensile su 5 anni)-0,24
Rapporto PE (ttm)N/D
EPS (ttm)-2,76
Prossima data utili05 ago 2024 - 09 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

    SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phas

  • GlobeNewswire

    Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

    Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and members of Anaptys senior management will discuss: PD-1 biology and rosnilim

  • GlobeNewswire

    Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

    53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131)Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patientsOnly one of 30 (3.3%) imsidolimab-treated patients had detectable ADA, which were non-neutralizingPlan to present comp